Krzysztof Landa, M.D. Health Technology Assessment – right and wrong use of HTA for treatment of ultrarare diseases - Orphan Drug Act - Document - PDFSEARCH.IO

First Page	Meta Content
	Krzysztof Landa, M.D. Health Technology Assessment – right and wrong use of HTA for treatment of ultrarare diseases Add to Reading List Document Date: 2014-12-08 11:13:50 Open Document File Size: 253,23 KB Share Result on Facebook Company NHF / / Country Japan / Poland / United States / United Kingdom / / Currency PLN / / IndustryTerm treatment of ultrarare diseases / analysed technology / / Organization FDA / Committee for Orphan Medicinal Products Orphan / European Union / / Person Michael Rawlins / Krzysztof Landa / / Position President / / Technology Orphan Medicinal Products Orphan technology / analysed technology / / SocialTag Pharmaceuticals policy Rare disease Orphan Drug Act Health Medicine Health economics Drug discovery Orphan drug

Krzysztof Landa, M.D. Health Technology Assessment – right and wrong use of HTA for treatment of ultrarare diseasesAdd to Reading List